Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology.

Auteurs : Fumagalli D, Blanchet-Cohen A, Brown D, Desmedt C, Gacquer D, Michiels S, Rothé F, Majjaj S, Salgado R, Larsimont D, Ignatiadis M, Maetens M, Piccart-Gebhart M, Detours V, Sotiriou C, Haibe-Kains B
Jaar : 2014
Journal : BMC Genomics
Volume : 15(1)
Pagina's : 1008

Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up?

Auteurs : Sonnenblick A, Fumagalli D, Sotiriou C, Piccart-Gebhart M
Jaar : 2014
Journal : Cancer Treat Rev
Volume : 40(9)
Pagina's : 1089-95

New Strategies in Breast Cancer: The Significance of Molecular Subtypes in Systemic Adjuvant Treatment for Small T1a,bN0M0 Tumors.

Auteurs : Sonnenblick A, Fumagalli D, Azim HA, Sotiriou C, Piccart-Gebhart M
Jaar : 2014
Journal : Clin Cancer Res
Volume : 20(24)
Pagina's : 6242-6

The AURORA initiative for metastatic breast cancer.

Auteurs : Zardavas D, Maetens M, Irrthum A, Goulioti T, Engelen K, Fumagalli D, Salgado R, Aftimos P, Saini KS, Sotiriou C, Campbell P, Dinh P, Von Minckwitz G, Gelber Rd, Dowsett M, Di Leo A, Cameron D, Baselga J, Gnant M, Goldhirsch A, Norton L, Piccart-Gebhart M
Jaar : 2014
Journal : Br J Cancer
Volume : 111(10)
Pagina's : 1881-7

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†

Auteurs : Piccart-Gebhart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, Noguchi S, Perez A, Rugo HS, Deleu I, Burris HA, Provencher L, Neven P, Gnant M, Shtivelband M, Wu C, Fan J, Feng W, Taran T, Baselga J
Jaar : 2014
Journal : Ann Oncol
Volume : 25(12)
Pagina's : 2357-62

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.

Auteurs : de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, Untch M, Jackisch C, Lang I, Smith I, Boyle F, Xu B, Barrios CH, Perez EA, Azim HA, Kim SB, Kuemmel S, Huang CS, Vuylsteke P, Hsieh RK, Gorbunova V, Eniu A, Dreosti L, Tavartkiladze N, Gelber Rd, Eidtmann H, Baselga J
Jaar : 2014
Journal : Lancet Oncol
Volume : 15(10)
Pagina's : 1137-46

Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer.

Auteurs : Rothé F, Laes JF, Lambrechts D, Smeets D, Vincent D, Maetens M, Fumagalli D, Michiels S, Drisis S, Moerman C, Detiffe JP, Larsimont D, Awada A, Piccart-Gebhart M, Sotiriou C, Ignatiadis M
Jaar : 2014
Journal : Ann Oncol
Volume : 25(10)
Pagina's : 1959-65

Hurdles and delays in access to anti-cancer drugs in Europe.

Auteurs : Ades F, Zardavas D, Senterre C, de Azambuja E, Eniu A, Popescu R, Piccart-Gebhart M, Parent F
Jaar : 2014
Journal : Ecancermedicalscience
Volume : 8(null)
Pagina's : 482

An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: The trastuzumab case.

Auteurs : Ades F, Senterre C, Zardavas D, de Azambuja E, Popescu R, Parent F, Piccart-Gebhart M
Jaar : 2014
Journal : Eur. J. Cancer
Volume : 50(18)
Pagina's : 3089-97

Genomic grade adds prognostic value in invasive lobular carcinoma.

Auteurs : Metzger-Filho O, Michiels S, Bertucci F, Catteau A, Salgado R, Galant C, Fumagalli D, Singhal SK, Desmedt C, Ignatiadis M, Haussy S, Finetti P, Birnbaum D, Saini KS, Berlière M, Veys I, de Azambuja E, Bozovic I, Peyro-Saint-Paul H, Larsimont D, Piccart-Gebhart M, Sotiriou C
Jaar : 2013
Journal : Ann Oncol
Volume : 24
Pagina's : 377-384

Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. (published online 11/2012)

Auteurs : Bidard FC, Fehm T, Ignatiadis M, Smerage JB, Alix-Panabières C, Janni W, Messina C, Paoletti C, Müller V, Hayes DF, Piccart-Gebhart M, Pierga JY
Jaar : 2013
Journal : Cancer Metastasis Rev
Volume : 32(1-2
Pagina's : 179-88

Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors.(epub nov 2013)

Auteurs : Awada A, Dumez H, Hendlisz A, Wolter P, Besse-Hammer T, Uttenreuther-Fischer M, Stopfer P, Fleischer F, Piccart-Gebhart M, Schöffski P
Jaar : 2013
Journal : Invest New Drugs
Volume : 31(3)
Pagina's : 734-41

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.

Auteurs : Goss PE, Smith IE, + collaborators (among others :, Piccart-Gebhart M, Finkelstein DM
Jaar : 2013
Journal : Lancet Oncol
Volume : 14(1)
Pagina's : 88-96

Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023.

Auteurs : Kerklaan BM, Diéras V, Le Tourneau C, Mergui-Roelvink M, Huitema AD, Rosing H, Beijnen JH, Marreaud S, Govaerts AS, Piccart-Gebhart M, Schellens JH, Awada A
Jaar : 2013
Journal : Cancer Chemother Pharmacol
Volume : 71(1)
Pagina's : 53-62

Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study.

Auteurs : Azim HA, Kroman N, Paesmans M, Gelber S, Rotmensz N, Ameye L, De Mattos-Arruda L, Pistilli B, Pinto A, Jensen MB, Cordoba O, de Azambuja E, Goldhirsch A, Piccart-Gebhart M, Peccatori FA
Jaar : 2013
Journal : J. Clin. Oncol.
Volume : 31(1)
Pagina's : 73-9

Pertuzumab: new hope for patients with HER2-positive breast cancer.

Auteurs : Capelan M, Pugliano L, de Azambuja E, Bozovic I, Saini KS, Sotiriou C, Loi S, Piccart-Gebhart M
Jaar : 2013
Journal : Ann Oncol
Volume : 24(2)
Pagina's : 273-82

Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial.

Auteurs : de Azambuja E, Zardavas D, Lemort M, Rossari J, Moulin C, Buttice A, Dhondt V, Lebrun F, Lalami Y, Cardoso F, Sotiriou C, Gil T, Devriendt D, Paesmans M, Piccart-Gebhart M, Awada A
Jaar : 2013
Journal : Ann Oncol
Volume : 24(12)
Pagina's : 2985-9

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.

Auteurs : Goldhirsch A, Winer EP, Coates AS, Gelber Rd, Piccart-Gebhart M, Thürlimann B, Senn HJ
Jaar : 2013
Journal : Ann Oncol
Volume : 24(9)
Pagina's : 2206-23

Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer.

Auteurs : Loi S, Michiels S, Lambrechts D, Fumagalli D, Claes B, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Piccart-Gebhart M, Joensuu H, Sotiriou C
Jaar : 2013
Journal : J. Natl. Cancer Inst.
Volume : 105(13)
Pagina's : 960-967

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

Auteurs : Goldhirsch A, Gelber Rd, Piccart-Gebhart M, de Azambuja E, Procter M, Suter TM, Jackisch C, Cameron D, Weber HA, Heinzmann D, Dal Lago L, Mcfadden E, Dowsett M, Untch M, Gianni L, Bell R, Köhne CH, Vindevoghel A, Andersson M, Brunt AM, Otero-Reyes D, Song S, Smith I, Leyland-Jones B, Baselga J
Jaar : 2013
Journal : Lancet
Volume : 382(9897)
Pagina's : 1021-8